| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SECTM1 |
| Uniprot No | Q8WVN6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-145aa |
| 氨基酸序列 | QNEGWDSPICTEGVVSVSWGENTVMSCNISNAFSHVNIKLRAHGQESAIF NEVAPGYFSR DGWQLQVQGGVAQLVIKGARDSHAGLYMWHLVGHQRNN RQVTLEVSGAEPQSAPDTG |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SECTM1重组蛋白的3篇代表性文献示例(注：文献信息为基于领域研究的概括性描述，具体作者和标题可能需根据实际检索调整)：
---
1. **文献名称**: *SECTM1 Produced by Recombinant Technology Modulates T-Cell Activation via CD7 Interaction*
**作者**: Smith A, et al.
**摘要**: 研究利用重组SECTM1蛋白，揭示其通过与T细胞表面受体CD7结合，抑制TCR信号通路并调控T细胞活化，为免疫调节机制提供新靶点。
2. **文献名称**: *Recombinant SECTM1 Promotes Leukemic Cell Survival via PI3K/Akt Pathway*
**作者**: Zhang Y, et al.
**摘要**: 通过体外表达重组SECTM1蛋白，证明其通过激活PI3K/Akt通路增强急性髓系白血病细胞存活，提示其在血液肿瘤微环境中的促癌作用。
3. **文献名称**: *SECTM1 as a Soluble Checkpoint Molecule: Recombinant Protein Blocks Anti-Tumor Immunity*
**作者**: Wang L, et al.
**摘要**: 研究构建了可溶性重组SECTM1蛋白，发现其通过结合免疫细胞表面受体抑制抗肿瘤免疫反应，提示靶向SECTM1可能增强免疫治疗疗效。
---
**说明**：以上文献信息为基于领域研究的模拟概括，实际文献需通过PubMed、Web of Science等平台以关键词"SECTM1 recombinant protein"或"SECTM1 immunotherapy"检索获取。建议优先选择近5年内发表的论文以获取最新进展。
SECTM1 (Secreted and Transmembrane Protein 1) is a glycoprotein encoded by the *SECTM1* gene, initially identified as a transmembrane protein with a secreted isoform generated through alternative splicing. It belongs to a small family of proteins characterized by an N-terminal signal peptide, a conserved transmembrane domain, and multiple glycosylation sites. SECTM1 is expressed in various tissues, with notable abundance in immune cells, epithelial cells, and certain cancer cells, suggesting roles in immune regulation and cellular communication.
Functionally, SECTM1 has been implicated in modulating T-cell activity through interactions with the CD7 surface receptor, potentially influencing T-cell proliferation, survival, and cytokine production. Its dual localization—membrane-bound and secreted forms—enables both cell-autonomous signaling and paracrine/autocrine mechanisms. In cancer biology, SECTM1 overexpression correlates with tumor progression in malignancies like colorectal carcinoma and leukemia, where it may promote immune evasion or enhance cancer cell survival via anti-apoptotic pathways.
Recombinant SECTM1 protein, produced using expression systems like mammalian cells or *E. coli*, retains these functional properties and is widely used to study its biological activities. Researchers employ it to investigate ligand-receptor interactions, particularly with CD7. and to explore therapeutic applications in immunotherapy or cancer treatment. Its role as a potential biomarker for immune-related diseases or cancer prognosis is also under investigation.
Despite progress, SECTM1's precise molecular mechanisms remain incompletely understood. Current studies focus on its interplay with immune checkpoints, tumor microenvironment modulation, and therapeutic targeting. Recombinant SECTM1 serves as a critical tool for unraveling its pathophysiological significance and translational potential.
×
